Energy News / Shareholders Foundation, Inc.

NASDAW:EDGE Long Term Shareholder Notice: Investigation of Potential Wrongdoing by Edge Therapeutics, Inc.

Via: ReleaseWire

Updated 1:15 PM CDT, Mon, July 09,2018

An investigation on behalf of current long term investors in Edge Therapeutics, Inc. (NASDAW:EDGE) shares over possible breaches of fiduciary duty by certain officers and directors was announced

San Diego, CA -- (SBWIRE) -- 07/09/2018 -- Certain directors of Edge Therapeutics, Inc. (NASDAW:EDGE) are under investigation over potential breaches of fiduciary duties.

Investors who are current long term investors in Edge Therapeutics, Inc. (NASDAW:EDGE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAW:EDGE stocks follows a lawsuit filed recently against Edge Therapeutics over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAW:EDGE stocks, concerns whether certain Edge Therapeutics directors are liable in connection with the allegations made in that lawsuit.

The plaintiff alleges that the Defendants failed to disclose that the Company's lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study, and that, as a result of the foregoing, the Company's financial statements and Defendants' statements about Edge's business, operations, and prospects, were materially false and misleading at all relevant times.

Those who purchased shares of Edge Therapeutics, Inc. (NASDAW:EDGE) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdawedge-long-term-shareholder-notice-investigation-of-potential-wrongdoing-by-edge-therapeutics-inc-1009103.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com